Description: |
A phase I,II safety and efficacy trial of the anti-VEGF agent TRC105 in metastatic, castrate resistant prostate cancer. The primary outcome measures are to define the maximum tolerable dose (MTD) of TRC105 given every two weeks and to determine if this dose of single-agent TRC105 is associated with a 6-month progression-free survival probability of 30%. |
Link: |
|
Site: |
NCI |
Principal Investigator: |
Bill Dahut |